CHF98.15
1.54% yesterday
SIX Swiss Exchange, Feb 21, 05:31 pm CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Stock price

CHF98.15
+8.79 9.84% 1M
-2.11 2.10% 6M
+9.45 10.65% YTD
+8.11 9.01% 1Y
+24.38 33.05% 3Y
+9.81 11.10% 5Y
+17.45 21.62% 10Y
SIX Swiss Exchange, Closing price Fri, Feb 21 2025
+1.49 1.54%
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key metrics

Market capitalization CHF193.86b
Enterprise Value CHF210.06b
P/E (TTM) P/E ratio 18.83
EV/FCF (TTM) EV/FCF 14.68
EV/Sales (TTM) EV/Sales 4.74
P/S ratio (TTM) P/S ratio 4.37
P/B ratio (TTM) P/B ratio 4.86
Dividend yield 3.57%
Last dividend (FY24) CHF3.50
Revenue growth (TTM) Revenue growth -1.03%
Revenue (TTM) Revenue CHF44.31b
EBIT (operating result TTM) EBIT CHF13.57b
Free Cash Flow (TTM) Free Cash Flow CHF14.31b
Cash position CHF12.20b
EPS (TTM) EPS CHF5.21
P/E forward 16.65
P/S forward 4.09
EV/Sales forward 4.44
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Novartis forecast:

6x Buy
21%
18x Hold
64%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Novartis forecast:

Buy
21%
Hold
64%
Sell
14%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
44,311 44,311
1% 1%
100%
- Direct Costs 11,487 11,487
12% 12%
26%
32,824 32,824
3% 3%
74%
- Selling and Administrative Expenses 5,735 5,735
24% 24%
13%
- Research and Development Expense 8,190 8,190
5% 5%
18%
18,898 18,898
2% 2%
43%
- Depreciation and Amortization 5,331 5,331
30% 30%
12%
EBIT (Operating Income) EBIT 13,567 13,567
16% 16%
31%
Net Profit 10,522 10,522
21% 21%
24%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
10 days ago
Die Schweizer Großbank UBS hat Novartis CH0012005267 von "Buy" auf "Neutral" abgestuft und das Kursziel von 111 auf 104 Franken gesenkt.
AD HOC NEWS
12 days ago
Novartis CH0012005267 kauft das US-Unternehmen Anthos Therapeutics für knapp eine Milliarde US-Dollar.
AD HOC NEWS
19 days ago
Deutsche Bank Research hat Novartis CH0012005267 von "Hold" auf "Buy" hochgestuft und das Kursziel von 100 auf 110 Franken angehoben.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today